National guidelines in the US and internationally endorse germline testing (GT) for Prostate cancer in patients with metastatic disease, high-risk disease, or with strong family cancer history to inform PCA treatment, screening, and hereditary cancer assessment. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00149-5/fulltext?rss=yes